Among them, Chengdu Ruiyuan Semiconductor is mainly engaged in the research and development, design, packaging and sales of power management chips, and one of its main products is DC/DC chips. A-share listed companies include Jingfeng Mingyuan, Fumanwei, Shanghai Beiling and Xidiwei, all of which have certain market share and competitiveness in the DC/DC chip market.Among them, Chengdu Ruiyuan Semiconductor is mainly engaged in the research and development, design, packaging and sales of power management chips, and one of its main products is DC/DC chips. A-share listed companies include Jingfeng Mingyuan, Fumanwei, Shanghai Beiling and Xidiwei, all of which have certain market share and competitiveness in the DC/DC chip market.In its view, this 10 billion M&A fund is not only 10 billion yuan, but also a way for the government to encourage and guide M&A through the amplification of M&A funds. "In short, whether it is the M&A fund of the integrated circuit design industry or the M&A fund of biomedicine, the core purpose is to guide the orderly development of the industry and avoid the dependence on the IPO path, leading to excessive competition in the industry."
Biomedicine, as one of the leading industries in Shanghai, has a scale of nearly one trillion yuan. In 2023, the industrial scale reached 933.732 billion yuan, an increase of 4.9%; Shanghai's biomedical industry chain is relatively complete, with many medical device enterprises and CRO, CMO and CSO enterprises. Therefore, Yuan Shuai believes that the Shanghai Municipal Government will set up a 10 billion yuan M&A fund for biomedical industry, which is expected to cultivate internationally competitive biomedical enterprises through mergers and acquisitions.[Shanghai 10 billion M&A Fund! 】In this regard, Bu Rixin believes that "chain owners" enterprises, as market-oriented institutions, set up CVC funds and will carry out horizontal and vertical mergers and acquisitions around the upstream and downstream of key industrial chains. "This kind of M&A will help chain-owner enterprises to expand their market scale and enhance their market competitiveness, which is the most in line with the logic of M&A and the basic logic of the Action Plan to encourage chain-owner enterprises to set up CVC funds."
In July this year, when Shanghai promoted the establishment of the parent fund of three leading industries with a total scale of 100 billion yuan, it said that it would focus on the three leading industries of integrated circuits, biomedicine and artificial intelligence, and give play to the functions of "investing early and investing small", industrial investment, merger and acquisition integration, and strengthening the chain, so as to improve the overall energy level and development level of the three leading industries in Shanghai."Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger."For the biomedical industry, Bu Rixin told the reporter of science and technology innovation board Daily that the investment cycle of biomedicine is generally long, and it needs to go through multiple stages from research and development to listing.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14